



MEDICAL TIPS

LIPONORM TABLETS

Issue IX, No. 36, 2022

Atorvastatin can delay arterial stiffness progression in hemodialysis patients

Elsayed MM & Ayman EM. Int Urology & Nephrology 2022

- Arterial stiffness is one of the vascular pathologies in hemodialysis (HD) patients with increased cardiovascular mortality and morbidity.
- In a double-blinded, placebo-controlled RCT on 50 patients undergoing regular HD, they were allocated to receive 10 mg of atorvastatin or placebo for 24 weeks.
- The aortic pulse wave velocity (PWV) as an indicator of arterial stiffness was measured from the base line to the end of 6 months.
- In the atorvastatin group there was no significant difference in the PWV and the central pulse pressure from the baseline whereas there was a significant increase in the PWV in the placebo group.

Arterial stiffness parameters remained stable in atorvastatin group but increased significantly in placebo-treated patients suggesting a potential role for atorvastatin to delay arterial stiffness progression in HD patients.

